| Company type | Subsidiary |
|---|---|
| Industry | |
| Founded | 1984 |
Number of employees | 1,128 |
| Parent | Eli Lilly and Company |
| Website | www.imclone.com |
ImClone Systems Incorporated was a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology.[1] It was founded in 1984 and had its corporate headquarters in Bridgewater, New Jersey, and its research headquarters in New York City.[1] On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully-owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL. Imclone lost its separate identity in 2014 when its former ImClone research and manufacturing sites were renamed Eli Lilly and Company.[2]
- ^ a b "ImClone Systems Corporation". Company Insight Center. Bloomberg Businessweek. Snapshot. Archived from the original on 2009-05-18. Retrieved 2013-12-25.
- ^ "Eli Lilly US Locations". R&D Locations. Eli Lilly and Company. Archived from the original on 20 October 2018. Retrieved 19 October 2018.